Dermal Sensitization
An in vitro screen to assess Dermal Sensitization with LLNA EC3 relevance
CeeTox can help you meet Amendment 7 and REACH directives and reduce or even replace the need for in vivo testing.
Download Dermal Sensitization PDF
Dermal Sensitization is a versatile test that can assess virtually any sample. When solubility is high, a standard culture system of immortalized human keratinocytes (HaCaT cells) is used as the test system. However, when finished products or chemicals with low solubility are evaluated, a 3D reconstructed human epidermis (RHE) model cultured at an air/liquid interface is used as the test system.
The CeeTox approach monitors the expression of up to 6 genes over concentration and time. Evaluation of the gene expression response in terms of magnitude, potency, and time allows an in vitro toxicity index (IVTI) to be calculated. Standard exponential regression analysis compares the IVTI to LLNA EC3 for a wide range of chemicals, allowing the EC3 value to be estimated and enabling a predictive value to be obtained (patent pending).
The proprietary method surpasses other in vitro methods that classify responses as merely positive or negative. Like the LLNA EC3 test, the approach can differentiate specific degrees of response, from non-sensitizer, very weak, weak, moderate, and strong, up to extreme.
The approach is cost effective, with a unit price up to 50% lower than GPMT or LLNA tests which makes it the right choice for screening large numbers of test articles efficiently.